INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

Beta Thalassemia icon

REBLOZYL provides substantial clinical benefit by reducing RBC transfusion burden1,2

RBC=red blood cell.

Syringe Icon

Learn about beta-thalassemia–associated anemia

Discover how ineffective erythropoiesis can impact beta-thalassemia patients.

Clipboard icon

REBLOZYL reduces transfusion burden1

The efficacy of REBLOZYL in patients with beta-thalassemia was demonstrated in the BELIEVE trial.

Dose titration icon

Optimize patient response through proper dosing1

REBLOZYL offers 2 dose levels for patients with beta-thalassemia. Learn how to titrate REBLOZYL to maximize clinical benefit.

RBC=red blood cell.

Beta Thalassemia icon

REBLOZYL provides substantial clinical benefit by reducing RBC transfusion burden1,2

RBC=red blood cell.

Syringe Icon

Learn about beta-thalassemia–associated anemia

Discover how ineffective erythropoiesis can impact beta-thalassemia patients.

Clipboard icon

REBLOZYL reduces transfusion burden1

The efficacy of REBLOZYL in patients with beta-thalassemia was demonstrated in the BELIEVE trial.

Dose titration icon

Optimize patient response through proper dosing1

REBLOZYL offers 2 dose levels for patients with beta-thalassemia. Learn how to titrate REBLOZYL to maximize clinical benefit.

RBC=red blood cell.

References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2022. 2. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219-1231.